TP53 and hyperinsulinemic hypoglycemia, familial, 4: Given the demonstrated value of molecular patterns in endometrial cancer (p53 mutation, POLE I mutational analysis, mismatch repair deficiency), next step will be to assess how inflammatory indicators may be used to refine patients prognosis and/or guide adjuvant therapies based on a molecular risk classification [41].